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Abstract
Ischemic renal injury is a complex syndrome; multiple cellular abnormalities cause accelerating cycles of
inflammation, cellular damage, and sustained local ischemia. There is no single therapy that effectively
resolves the renal damage after ischemia. However, infusions of normal adult rat renal cells have been a
successful therapy in several rat renal failure models. The sustained broad renal benefit achieved by
relatively few donor cells led to the hypothesis that extracellular vesicles (EV, largely exosomes) derived
from these cells are the therapeutic effector in situ. We now show that EV from adult rat renal tubular cells
significantly improved renal function when administered intravenously 24 and 48 hours after renal ischemia
in rats. Additionally, EV treatment significantly improved renal tubular damage, 4-hydroxynanoneal adduct
formation, neutrophil infiltration, fibrosis, and microvascular pruning. EV therapy also markedly reduced
the large renal transcriptome drift observed after ischemia. These data show the potential utility of EV to
limit severe renal ischemic injury after the occurrence.
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Abstract
Renal ischemia causes and frequently worsens existing AKI  and CKD.  AKI is morbid, potentially
lethal,  and an emergent medical problem.  Unfortunately, there is no effective therapy for AKI.  The
medical failure to affect ischemic AKI is not surprising given its unpredictability and inherent
complexity.  Therefore, it is unlikely that this broad organ malfunction can be corrected by targeting
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single dysfunctional processes.  The realization that renal ischemia also aggravates progressive CKD,
regardless of its initial cause, is an additional impetus in the search for solutions.  In this report, we
describe the use of renal cell extracellular vesicles (EV) to treat ischemic renal injury in rats. We derived
this work from prior experimentation that showed improved renal function and structure by relatively small
numbers of infused renal cells.  We suggest that the beneficial effect of those donor cells was due to
their EV, and tested the hypothesis that renal EV can protect ischemic kidneys.
Ischemic preconditioning (IPC) is a highly conserved adaptation in which transient, sublethal ischemia
protects from subsequent ischemic injury.  However, translating the powerful effects of IPC to treat
unpredictable renal ischemia is not feasible.  It is not known how IPC confers protection, although an
important clue is that IPC can be transferred by the blood of IPC donors,  i.e., remote IPC (RIPC). One
possible mechanism of RIPC transfer is by EV, released membrane-bound nanovesicles that mediate cell-to-
cell communication and convey the distinctive state of originating cells.  In this work, we show that EV
from adult rat renal tubular cells can be delivered by peripheral vein to successfully treat rats with
established severe ischemia/reperfusion AKI. Furthermore, EV from hypoxia preconditioned (IPC) cells are
more effective, providing greater improvements in renal phenotype and genotype than EV from normoxic
cells.
Results
EV
We employed two sets of EV (exosomes) derived from the same primary rat renal tubular cells: one set
maintained in normoxic conditions (EXO) and the other exposed to 1% O  hypoxia for 4 hours before
collection of EV (IPC EXO). Cell number and EV protein content, size, and vesicle number were not
different between EXO and IPC EXO (Table 1). Nano tracker analysis (Supplemental Figure 1) and electron
microscopy showed similar size distribution between EV groups. The EV contained mRNAs encoding the
male determinant SRY gene as well as the transfected serum amyloidA1 transcript. These were used to track
EV in recipient kidneys. In addition, EV tracking was achieved by labeling a 10% fraction of EV with red
Exo-Glow. This maneuver showed the exosomes broadly distributed within the kidney (Figure 1). Cell
culture studies demonstrated that EV were rapidly taken up by proximal tubular epithelia; IPC EXO more
than EXO (Supplemental Figure 2). This result is consistent with higher levels of adherent intercellular cell
adhesion molecule1 (ICAM1),  which reportedly promotes EV cell fusion  (Figure 1).
Renal Function
Four groups of five Sprague Dawley (SD) rats were studied: sham surgery (controls), bilateral renal
ischemia injected with saline vehicle (untreated ischemia), or with EV from renal cells cultured under
normoxic conditions (EXO), or with EV from posthypoxic kidney cells (IPC EXO). The sample size was
determined by power analysis.  The goal was to treat after the injury and EV or saline vehicle were given
intravenously 24 and 48 hours postischemia. There was a rapid and similar increase in serum creatinine in
all ischemic groups after 24 hours, and it decreased slowly in the ischemic rats given saline (Figure 2). In
contrast, creatinine improved rapidly in ischemic rats injected with EXO, and the recovery was even faster
in rats treated with IPC EXO (P<0.02 versus EXO). Creatinine levels in sham-operated rats remained within
normal limits (Figure 2). Similarly, serum urea nitrogen demonstrated accelerated recovery in the
postischemic rats treated with EXO or IPC EXO (not shown). Untreated ischemic rats (saline) also had
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abnormally large kidneys, and EV, particularly IPC EXO (P<0.01), significantly limited organomegaly,
likely a reflection of improved inflammation and fibrosis. No mortality was observed.
Renal Phenotype and Genotype
Untreated renal ischemia caused severe disruption of renal architecture, including tubular congestion and
simplification, intratubular obstruction with casts, and inflammation (as compared with sham-operated
controls, Figure 3A). In contrast, injection of EXO, and more so IPC EXO, limited each of these histologic
abnormalities (Supplemental Figure 3). Heat-inactivated EV were ineffective in limiting postischemic injury
(Supplemental Table 1), consistent with a role of EV RNA or specific proteins in the protection observed.
Thus, comprehensive genetic profiling was performed and revealed significant activation of both pro- and
antiapoptotic transcripts in untreated postischemic kidneys, when compared with sham and IPC EXO groups
(Figure 3). Renal injury in untreated ischemia also included enhanced cellular proliferation, as indicated by
higher protein levels of proliferative cell nuclear antigen (PCNA, a cell proliferation marker), as reported.
Treatment with EXO or IPC EXO limited the proliferative postischemic response (Supplemental Figure 4).
Although tubular cell proliferation contributes to recovery, proliferation of leukocytes and fibroblasts is
detrimental,  thus lower proliferation in the treated groups is likely a manifestation of decreased tubular
injury.
The role of EV on oxidant stress induced by ischemia was examined in sections stained for 4-
hydroxynonenal adducts (HNE).  Whereas renal HNE formation was nearly undetectable in sham rats,
strong HNE formation existed in untreated ischemic rats (Figure 3B); EXO and IPC EXO significantly
limited the HNE labeling. Analysis of specific redox transcripts indicates that ischemia alters redox balance
as compared with either sham or IPC EXO groups. Thus, treatment with EV from preconditioned cells (IPC
EXO) restores renal genetic profiles to near that of nonischemic (sham) animals.
Renal inflammation complicates renal ischemia  and, among the aggregates of renal inflammatory cells,
short-lived neutrophils  point to ongoing inflammation.  Neutrophils in sham kidneys were rare, whereas
kidneys from untreated ischemic rats contained large numbers of neutrophils (Figure 3C). In contrast, EXO
and IPC EXO curtailed renal neutrophil accumulation postischemia. Another sensitive indicator of
inflammation postischemia is upregulation of renal complement components.  In Figure 3D, we show that
glomerular C3 immuno-reactivity, near background in sham operated rats, was markedly increased in
untreated ischemia. In contrast, EXO, and particularly IPC EXO, attenuated C3 protein expression.
Moreover, the renal transcriptome in ischemia revealed broader activation, including C2, C3, and C4, with
attenuation of the membrane attack complex inhibitor CD55. We also found activation of mRNAs encoding
proinflammatory chemokines, cytokines, and adhesion molecules. These responses were suppressed by
EXO and IPC EXO treatment, with significantly lower levels of proinflammatory transcripts in the IPC
EXO group.
Substantial peritubular fibrosis followed renal ischemia within 6 days (Figure 3E). Treatment with EXO
significantly limited the broad activation of profibrotic genes and decreased renal fibrosis. Infusions of IPC
EXO were even more effective at limiting fibrosis in postischemic kidneys. It is noteworthy that ischemia
upregulated genes that break down extracellular matrix, including MMP2, 7, 11, and 14, but also the MMP
inhibitor TIMP1. IPC EXO limited the amplitude of these ischemic responses.
Renal ischemia severely compromised the renal microvasculature, consistent with prior observations.
Renal sections, labeled with Lycopersicon Esculentum lectin (LEL), showed severe loss of capillaries, or of
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their lectin epitopes, in kidneys from untreated postischemic rats (Figure 3F). This vascular rarefication was
prevented, in part, by EXO, and, for the most part, by IPC EXO. The renal genotype revealed that ischemia
suppressed angiogenesis, in that angiostatic genes were activated whereas proangiogenic genes were
inhibited. These antiangiogenic effects were antagonized by IPC EXO. Although renal ischemia severely
decreased glomerular number (2.49±0.2/hpf versus 5.58±0.2 in sham), glomeruli were relatively preserved
after EV treatment (3.46±0.2 in EXO; 4.12±0.2 in IPC EXO; P<0.001 versus untreated ischemia).
Western Blots
Three groups of proteins were measured on immunoblots; catalase (CAT) and SOD1 are constituents of the
antioxidant system. Components of the hypoxia inducible factor (HIF) pathway, vascular endothelial growth
factor (VEGF), glucose transporter1 (GLUT1 or Slc2a1), and erythropoietin (EPO), were included. Heat
shock protein 27 (Hsp27) was included as a presumptive reno-protective protein. At 6 days postischemia,
levels of CAT, SOD1, VEGF, EPO, and GLUT1 were reduced in untreated ischemic rats. However,
treatment with IPC EXO largely prevented loss of these proteins. On the other hand, protein levels of renal
HIF were not different 6 days postischemia (not shown). In contrast, Hsp27 protein levels were elevated
postischemia, and IPC EXO treatment prevented Hsp27 upregulation (Supplemental Figure 5). Consistent
with histologic and RNAseq data, immunoblots also showed increases in TGFb1, fas, and BIRC3
postischemia; these were all prevented with EV treatment (Supplemental Figure 6).
mRNA Pathways
Sequencing by RNAseq identified 12,159 renal transcripts. There were 3141 renal genes significantly
altered in untreated ischemia as compared with the normal (sham) group. The number of altered genes was
reduced to 1599 in the EXO-treated postischemic group, and IPC EXO further reduced the number to 71
altered transcripts, or only 2% of those altered in the untreated ischemic group. Hence, renal ischemia
markedly altered the normal renal transcriptome. However, EXO treatment partly corrected and IPC EXO
nearly fully corrected the large drift caused by ischemia. These effects can be visualized on a
multidimensional scaling plot which reports the distances, or the inverse of similarities, among the groups (
Figure 4). Distances on the multidimensional scaling plot correspond to leading log–fold changes between
each pair of samples. The leading log–fold change is the average (root mean square) of the largest absolute
log–fold changes between each pair of samples. The dimensions on the plot are leading log–fold changes,
and demonstrate the genetic drift postischemia and its almost complete correction by IPC EXO. It is also
noted that significant differences in gene expression among the four groups were determined by the false
discovery rate (FDR<0.05), and only those genes that met this cutoff were included.
All transcriptomes were then used for pathway analysis with WebGestalt (Vanderbilt University, Nashville,
TN), and the generated data sets were incorporated into well defined KEGG pathways
(http://www.genome.jp/kegg/pathway.html; Kyoto University, Japan). The pathways altered postischemia
included, in descending order of statistical significance, metabolic, cell proliferation, focal adhesion, solute
absorption, cell cycle, extracellular matrix receptor interaction, oxidative phosphorylation, glutathione
metabolism, phagosome, apoptosis, cytokine-cytokine receptor interaction, and DNA replication
(Supplemental Table 2). Compared with sham, renal ischemia caused the largest changes in metabolic
pathways. Specifically, the largest number of altered transcripts were involved in metabolism and achieved
the highest statistical significance. Treatment with IPC EXO effectively corrected the perturbations in
metabolic gene expression such that expression was similar to sham (P>0.05). Postischemia, renal
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transcripts were partly normalized by IPC EXO treatment; 1526 were significantly higher and 1593 lower
than in untreated rats. A subset of these transcripts was also corrected by EXO treatment. In analyzing the
transcripts protected by both IPC EXO and EXO treatment we found 39 antiapoptotic and 29 anti-
inflammatory transcripts. The most significant KEGG pathway was metabolic and by GO analysis it was
transporter activity (Supplemental Figure 7).
RNAseq was used to measure 312 EV transcripts in RNA extracted from EXO and IPC EXO. There were
24 differentially expressed transcripts between EXO and IPC EXO (Supplemental Table 3). Ribosomal
RNAs were abundant in renal EV, as shown by others.  mRNAs encoding cytoplasmic ribosomal proteins
Rps6 (2.3-fold) and Rps13 (1.3-fold) were also upregulated in IPC EXO. In contrast, mRNAs for structural
Rn28S (0.28) and Rn45S (0.30) appeared suppressed (Supplemental Table 3). IPC EXO also carried higher
mRNA levels for Drd4 (78-fold increased), a gene that protects from ischemic injury,  as well as Lrrc56
(16-fold increased), and Ptdss2 (eight-fold increased). Interestingly, Ptdss enhances recovery from ischemic
injury.  IPC EXO also contained higher levels of Eps8l2 (4.5-fold increased), a transcript involved in actin
remodeling.  Phrf1, a transcript that participates in RNA processing,  was increased 3.9-fold. Ugt2b1 and
Ugt2b10, genes that encode detoxification enzymes reportedly suppressed by hypoxia,  were each
increased 3.2-fold. Rassf7, a transcript activated by hypoxia that regulates microtubule dynamics,  was
increased 2.9-fold. Although our EV mRNA compendium is not complete and its contents likely reflect only
a portion of the entire renal EV library,  we detected significant differences between IPC EXO and EXO
among the 312 EV transcripts measured. The most significantly altered transcripts detected by Kegg
pathway analysis were associated with the ribosome whereas GO analysis detected alterations in RNA
processing (Supplemental Figure 8).
Discussion
Ischemic injury to the kidney and other organs can be deadly. Even with subsequent recovery, AKI is still
linked to short- and long-term mortality.  Chronic/recurrent renal ischemia also promotes the progression
of CKD to ESRD.  Moreover, ischemic AKI is common in transplanted kidneys, and is the main cause
of delayed graft function.
Unfortunately, there is no specific therapy for ischemic AKI, and supportive care has not improved
outcomes.  Thus, new approaches to AKI are needed. Animal and human data are consistent, showing that
no single pathogenic event can be targeted to completely halt ischemic renal injury. Instead, data suggest
that multiple abnormalities are intertwined in an expanding cycle of ischemia and inflammation.
To provide a multifaceted therapy, we have transplanted adult renal tubular cells in experimental AKI and
CKD.  The advantages of organ-specific cells for repair have been documented.  These studies
led to the hypothesis that the relatively small number of donor cells infused  acted at a distance on
endogenous cells. Accordingly, we described the presence of growth factors and SAA1 protein in
conditioned medium of donor cells.  This report is consistent with data of others using conditioned
media.  We further hypothesized that exosomes or EV released from transplanted cells, and in
conditioned medium, serve as a therapeutic agent that improves kidney function. Furthermore, we
postulated that EV communicate an “IPC state.” Unfortunately, translating the powerful effect of IPC to the
clinical arena is not feasible, because most ischemia is unpredictable, and inducing ischemia in a vital organ
to prevent possible future injury is unethical.  There are dozens of conflicting RIPC human trials, using
diverse strategies (ClinicalTrials.gov). However, not knowing the mechanism of RIPC hinders design and
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implementation.  Here, we tested the hypothesis that EV transfer is one mechanism of RIPC.
There are several points to be emphasized: Ischemic damage was marked by oxidative stress footprints as
well as renal neutrophil infiltration and complement activation, likely in situ. Within 6 days, extensive
fibrosis and loss of peritubular capillaries  and glomeruli were seen. These postischemic changes were
largely abrogated by EXO treatment, and greater improvements were seen with IPC EXO in virtually all
parameters evaluated. Additionally, when the two groups, EXO and IPC EXO, are taken together (ten rats),
the comparison strongly indicates that exosomes are superior to either vehicle (saline) or heat-inactivated
exosomes postischemia. We acknowledge similarities in EXO and IPC EXO EV protection, suggesting that
EXO EV were derived from cells that might have had some degree of hypoxic stress in normal culture.
Multilayered ischemic damage was also manifested by suppressed antioxidant and HIF pathway proteins
which were improved with IPC EXO treatment. It is also noteworthy that EV limited ischemia-induced
activation of renal HSP27, suggesting that some stress responses were not required after EV treatment. It is
remarkable that EV administration was successful well after renal ischemia, indicating that EV infusions are
potentially therapeutic. This latent period also suggests that endogenous renal mechanisms allow survival
for a time before treatment.
The renal transcriptome analysis revealed a major drift in transcriptomes postischemia away from normal
(sham), whereas IPC EV largely contained the drift. Gene pathway analysis revealed drastic modifications
by ischemia whereas IPC EXO prevented most alterations. These findings are consistent with a state of
mixed renal dysfunction and dormancy/“stunning” for up to 24 hours after severe ischemia, which is partly
resolved by IPC EXO. We presume that structural and cargo differences between EXO and IPC EXO might
account for what may be differences in activity, i.e., due to greater membrane fusion potential, via ICAM1,
or to transcripts that stabilized dormant ischemic cells in the IPC EXO group. We hypothesize that abundant
ribosomal transcripts in IPC EXO and EXO might facilitate the transition from dormancy to restoration of
function by reversing hypoxia-dependent inhibition of protein synthesis.  In summary, treatment with EV
from adult renal cells applied well after renal ischemia improved multiple parameters of structure, function,
and transcriptome profile.
Concise Methods
Primary Renal Tubular Cells and EV
Primary renal tubular cells were obtained from male SD rats (Charles River, Wilmington, MA). All
experiments were conducted in conformity with the “National Institutes of Health guide for the care and use
of laboratory animals.” The rats were euthanized by removing both kidneys under general anesthesia. The
kidney cortices were minced in S1 medium (below), and digested with type 4 collagenase (Worthington,
Lakewood, NJ), 6 mg/dl, at 37°C in 38% O  and 5% CO  for 50 minutes. The renal tubules were then
separated by percoll gradient,  cultured for 3 days, and the tubular cells, now in monolayers, were
transfected with pcDNA3.1-SAA1 (2 μg/ml) plasmid. pcDNA3.1-SAA1 was manufactured and sequenced
in our laboratory, and its construction was previously reported.  This plasmid is used because
tubulogenic SAA1 can be used to track transfer to host kidney cells  from donor EV (Figure 1). In addition,
male determinant gene SRY was used to track donor male EV in recipient female kidneys. Transfection was
performed with lipofectamine 2000 (Life Technologies, Grand Island, NY); efficiencies were >70%.  The
transfected cells were cultured in S1 medium: Each 2 L contains F-12 HAM, 10.7 g; DMEM, 8.32 g; L-
glutamine, 0.29 g; HEPES, 4.78 g; sodium selenite, 1.7 μg; sodium pyruvate, 0.110 g; 3.2 ml phenol red and
40
67
2 2
17
,16 17
19
19
Renal Tubular Cell-Derived Extracellular Vesicles Accelerate the Recovery of Established Renal Ischemia Reperfusion Injury
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698065/?report=printable[6/5/2019 3:33:53 PM]
pH was adjusted to 7.4 with sodium bicarbonate (Sigma). S1 medium was supplemented with hepatocyte
growth factor, 200 ng/ml, and EGF, 400 ng/ml (R&D Systems, Minneapolis, MN). The medium also
contained hydrocortisone, 100 μg/ml; insulin, 35 μg/ml; transferrin, 32 μg/ml; sodium selenite, 42 ng/ml
(Sigma, St. Louis, MO), with 10% FCS. The following day, renal tubular cells were divided into two
groups: one group was placed in a hypoxic chamber (SCI-tive Dual; Baker Ruskinn, Sanford MA), 1%
O /5% CO , and the other continued in 38% O /5% CO  for 4 more hours. The culture medium of both
groups was then changed to oxygenated S1 medium with 10% FCS previously depleted of EV by 100,000 ×
g centrifugation twice for 90 minutes. The cells were cultured for 3 more days, and cell medium collected
for EV isolation. The time periods of hypoxia and exosome collection were chosen on the basis of pilot
studies in which survival of hypoxic cultured cells and exosome number were maximized. The medium was
subjected to sequential centrifugation, 300 × g for 10 minutes, recovering supernatant; 2000 × g for 10
minutes, recovering supernatant; 10,000 × g for 30 minutes, recovering supernatant; and then 100,000 × g
for 70 minutes twice, recovering the pellet. The EV pellet was suspended in 500 μl of PBS, and filtered
through a 1.0 μM filter and then a 0.2 μM filter. The EV protein was measured with the Pierce Coomassie
Plus (Bradford) Assay Kit (23236; Thermo Fisher Scientific). The EV were characterized by electron
microscopy and by detecting EV CD63 on immunoblots (Figure 1).  Nanotrack analysis was performed
using ZetaView (Particle Metrix, Mebane, NC) according to the supplier’s instructions. A third group of EV
consisted of IPC EV heated at 60°C for 45 minutes to inactivate mRNA.
Animal Protocols
At 8 weeks of age, female SD rats were anesthetized with inhaled isoflurane (0.5%–1%) and placed on a
homeothermic table to maintain a body core temperature at approximately 37°C. In three groups of rats
(below) both renal pedicles were occluded for 50 minutes with microaneurysm clamps, as described.  In
a fourth rat group, sham rats had an identical surgical procedure except that the renal pedicles were not
clamped. The rats received EV 24 and 48 hours (equivalent quantities [100 μg] protein in 0.5 ml of sterile
physiologic saline) after surgery via the tail vein. Blood samples were obtained daily from the saphenous or
tail veins. Two doses were given to increase efficacy because we hypothesize that exosome release from
engrafted cell transplants occurred over time on the basis of prior studies.  Euthanasia occurred 6 days
after ischemia: after ensuring adequate anesthesia with isoflurane, organs were removed and fixed in 3.8%
paraformaldehyde. A fifth group was subjected to ischemia (as above) and received heat-inactivated EV at
24 and 48 hours after surgery.
Histology and Immunohistochemistry
Kidneys were fixed in 3.8% paraformaldehyde, paraffin embedded, and 5-μM sections obtained for
Masson’s trichrome to stain connective tissue, and periodic acid Schiff (PAS) to image cellular morphology.
The percentage of tubules in the outer medulla that showed epithelial necrosis, luminal debris, and/or
tubular dilation was estimated on coded sections without the knowledge of the experimental group to which
the animals belonged.  Further quantification of congestion, intratubular obstruction (casts), inflammation,
and tubule simplification was graded in cortex and medulla on the following scale: 0 = none, 1+ = <10%, 2+
= 10%–25%, 3+ = 26%–75%, 4+ = >75%.  Renal neutrophils were visualized with primary anti-rat
neutrophil rabbit antibody (ABIN2586050; antibodies-online.com) and secondary antibody with HRP tag
(SK-4805; Vector, Burlingame, CA). The neutrophils were counted in blinded renal sections. The areas of
glomerular and peritubular fibrosis were quantified using Metamorph imaging image processing software
(Sunnyvale, CA) and expressed as fractional areas per 200× microscope field, covering all available
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surfaces in all coded kidneys. Atrophic tubules were counted in blinded PAS-stained sections. Renal
sections were immunostained for HNE to estimate tissue peroxidation. The primary HNE rabbit antibody
was applied at 1:300 dilution (ABIN873270; antibodies-online.com). Horse anti-rabbit antibody was used to
develop: ImmPRESS HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit (MP-7401; Vector).
Additional kidney sections made to visualize the microvasculature by immunofluorescence: kidneys were
immersion-fixed in 3.8% paraformaldehyde, followed by cryoprotection in 20% sucrose/PBS, and mounting
in optimal cutting temperature compound. Serial cross-sections (10 μm thick) were cut on a cryostat and
mounted, and fixed to slides in 100% methanol at −20°C for 10 minutes and PBS-washed twice, followed
by treatment with 0.3% Triton X-100 for 5 minutes and then PBS-washed twice. Sections were incubated
with Lycopersicon Esculentum (Tomato) Lectin, conjugated with Alexa Fluor 594 (DL-1177; Vector) at
1:300, overnight at 4°C. DAPI (Molecular Probes, Eugene, OR) was applied at 300 nM for 5 minutes at
room temperature. Images were taken through an inverted microscope (Zeiss Axio Imager.D2, Oberkochen,
Germany). Positive fluorescence was quantified from >10 sections per animal by Aperio’s Positive Pixel
Count algorithm (Aperio Technologies, Inc., Vista, CA). Negative controls for all targets were analyzed to
ensure that the algorithm detected minimal false-positives and autofluorescence. Microvascular density was
expressed as fractional positivity (positive pixels/total pixels on each of 400× fields per rat kidney).
Immuno (Western) Blotting
Kidney cortices were homogenized in 25 mM Tris, pH 7.6, 150 mM NaCl, 1% deoxycholate, 1% P-40,
0.1% SDS, and 2× Halt Protease Inhibitor Cocktail (Thermo Scientific, Rockford, IL) and adjusted to a
protein concentration of 2 mg/ml. The homogenates (20 µg) were fractionated by electrophoresis through
16.5% polyacrylamide Tris-Tricine gels. After electrophoresis, proteins were transferred to a nitrocellulose
membrane. Blocking was carried out in 1% casein, 1× PBS for 1 hour. Incubation with primary antibody
diluted in 1× PBS was for 1 hour. The following rabbit primary antibodies were from Abcam, Cambridge,
MA: anti-SOD (1:1000, ab52950); anti-catalase (1:2000, ab16731); anti-erythropoietin (1:500, ab135390);
anti-GLUT1 (1:250, ab652); anti-HSP27 (1:1000, ab5579); anti-actin (1:1000, ab8227), and mouse anti-
actin (1:50,000, Ab6276). Anti-VEGF (1:500, sc507) and anti-CD63 (1:250, sc15363) were from Santa
Cruz Biotechnology, Santa Cruz, CA. Goat anti-ICAM1 (1:200, af583) was from R&D Systems. Mouse
anti-PCNA (1:3000, p8825) was from Sigma. Secondary antibodies were from Li-COR Biosciences,
Lincoln, NE: IRDYE800CW donkey anti-rabbit (green, 1:15,000, 926–32213), IRDYE 680RD donkey anti-
rabbit (red, 1:20,000, 926–68073), IRDYE800CW donkey anti-mouse (green, 1:15,000, 926–32212),
IRDYE 680RD donkey anti-mouse (red, 1:20,000, 926–68072), and IRDYE 680RD donkey anti-goat (red,
1:20,000, 926–68074). The membrane was then washed in 1× PBS and incubated with secondary antibodies
diluted in 1× PBS for 1 hour. Secondary antibodies were IRDye 680RD goat anti-rabbit IgG (1:15,000) (Li-
COR Biosciences) and IRDye 800 CW goat anti-mouse IgG (1:20,000) (Li-COR Biosciences). After
washing in 1× PBS, the filter was scanned using an Odyssey Infrared Imaging System (Li-COR
Biosciences) for visualization of immunoreactive proteins. All steps were carried out at room temperature.
Electron Microscopy
EV were fixed in 2% paraformaldehyde/2% glutaraldehyde/0.1 M phosphate and then adsorbed to a 200–
400 mesh carbon/formvar coated grid and the negative stain (NANOVAN; Nanoprobes, Yaphank, NY)
added. The EV were visualized by electron microscopy  (Tecnai G2 12 Bio TWIN Microscope [FEI,
Hillsboro, OR] equipped with an AMT CCD camera [Advanced Microscopy Techniques, Danvers, MA]).
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Renal and EV SAA1 and SYR mRNA
RT-PCR was also used to amplify SAA1 mRNA in recipient kidneys and EV. RNA extracted from
homogenized renal cortices in lysis buffer was isolated with a purification kit as recommended by the
vendor (CAT # 12183–555; Invitrogen), and cleaned with an RNeasy Mini kit as recommended by the
vendor (CAT # 74104; Qiagen, Valencia, CA). For RT-PCR, 2 µg of total RNA were used to synthesize
cDNA with an AffinityScript QPCR cDNA Synthesis Kit as recommended by the vendor (CAT # 600559;
Agilent Technologies, Santa Clara, CA). The murine SAA1 mRNA was amplified as previously described
using the following primers:
F: 5′-GA GTC TGG GCT GAG AA-3′
R: 5′-TG TCT GTT GGC TTC CTG GT-3′
The PCR products were separated in a 2.5% agarose gel.
The specific SRY DNA was amplified from extracted kidney and EV using the following primers :
F:5′-AAGCGCCCCATGAATGC-3′
R: 5′-AGCCAACTTGCGCCTCTCT-3′
The PCR products were separated in a 2.5% agarose gel.
RNAseq and Differential Gene Expression
Whole renal and EV transcriptomes by RNAseq analysis  were obtained by the Center for Medical
Genomics, Indiana University School of Medicine sequencing core facility. Kidney total RNA and EV RNA
were first evaluated for quantity and quality, using an Agilent Bioanalyzer. For kidney RNA quality, an
RNA integrity number of seven or higher was required. The starting amount of RNA for library preparation
was 500 ng for EV RNA and 1000 ng for kidney total RNA. PolyA mRNA capture of total RNA was
performed using a Dynabeads mRNA DIRECT Micro Kit (61021; Ambion) as the first step. cDNA library
preparation followed, inclusive of enzymatic fragmentation, hybridization and ligation of adaptors, reverse
transcription, size selection, and amplification with barcode primers, following the Ion Total RNA-Seq Kit
v2 User Guide, Pub. No. 4476286 Rev. E (Life Technologies). Each resulting barcoded library was
quantified and its quality accessed by an Agilent Bioanalyzer, and multiple libraries pooled in equal
molarity. Eight microliters of 100 pM pooled libraries were then applied to the Ion Sphere Particles (ISP)
template preparation and amplification using Ion OneTouch 2 (Life Technologies), followed by ISP loading
onto a PI chip and sequencing on an Ion Proton semiconductor (Life Technologies). Each PI chip allows
loading of about 140 million ISP templates, generating approximately 80–100 million usable reads, up to
10–15 Gb. The reads were then mapped to the rat genome rn5 using TopHat2.  Gene-based expression
levels were quantified with NGSUtils.  Read counts were normalized to the total number of sequencing
reads falling into annotated gene regions in each sample, and further scaled on the basis of a trimmed mean
of log-transformed counts per million (CPM) to correct for the variability of RNA composition in each
sample.  The genes with less than one read per million mappable reads in no less than half of samples in at
least one condition were removed. The scaled CPM was used as gene-level quantification in each sample.
The package “edgeR” was utilized to identify the genes that were differentially expressed between different
biologic conditions.  Benjamini and Hochberg’s algorithm was used to control the FDR. We determined
FDR≤0.05 as the statistical cutoff for differential expression among different conditions. WEB-based GEne
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SeT AnaLysis Toolkit WEBGestalt (http://bioinfo.vanderbilt.edu/webgestalt/)  was used to integrate the
differentially expressed transcripts to the centrally curated database, KEGG (Kyoto Encyclopedia of Genes
and Genomes), and to create functional categories with those differentially expressed transcripts. We
performed several comparisons of renal transcripts: sham (control) and untreated ischemic; sham and
normoxic EV (EXO); or sham and IPC EV. The IPC EV transcripts were separately compared with the
normoxic EV (EXO).
Statistical Analyses
Sample size of five animals in each group gave 90% power to detect differences of 0.3 mg/dl in serum
creatinine (with α set at 0.05).  Data are expressed as mean±1 SEM. ANOVA was used to determine if
differences among mean values reached statistical significance. Paired t test (two tailed, two sample,
unequal variance) was used for comparisons between groups (GraphPad Prism, LaJolla, CA). Tukey’s test
was used to correct for multiple comparisons. The null hypothesis was rejected at P<0.05.
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Figures and Tables
Table 1.
Exosome parameters
Parameter EXO IPC EXO P Value
Cells/flask 12.9×10 ±7×10 13.4×10 ±5×10 NS6 5 6 5
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Protein/flask, μg 70±7 91±29 NS
Vesicle number/flask 1.2±0.1×10 1.1±0.07×10 NS
Mean EV size, nm 100±3.94 106±3.78 NS
Data are mean±SEM. EV derived from normoxic (EXO) and IPC renal cells were comparable in size and number.
Figure 1.
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Open in a separate window
Donor EV in recipient kidneys. (A and B) ICAM1 and CD63 protein levels in normoxic EV (EXO) and IPC EV (IPC
EXO), measured on western blot, n=5. ICAM1 was higher (P=0.001) and CD63 lower (P<0.01) in IPC EXO. (C) Electron
microscopy showed IPC EXO and EXO (not shown) averaged <200 nM diameter. (D) RT-PCR was used to identify the
SRY male determining gene in EV (EXO) from male donor cells (positive control), and also in kidneys of female EV
recipients (IPC EXO and EXO), but not in female kidneys of rats injected with saline (saline). Additional SRY-positive
controls were amplified from normal male rat kidneys. (E) Representative image of three rat kidneys used to localize IPC
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EV labeled with red EXO-Glow. A 10% fraction of IPC EV was labeled, remixed with the unlabeled 90%, injected, and
visualized by fluorescent microscopy in 50-μM vibratome sections. (F) RT-PCR was used to identify the murine SAA1
gene amplified in donor EV derived from cells transfected with SAA1 (EXO), and also in recipient kidneys of rats injected
with EXO and IPC EXO (EXO and IPC EXO), but not in kidneys of rats injected with saline (saline). The negative and
positive controls were amplifications of pCDNA1 and SAA1-pCDNA1 plasmids used for transfection. Ctrl, control; MW,
molecular weight; pos, positive.
Figure 2.
Improved renal function and kidney weight after treatment with EV. Left: Serum creatinine levels in the four groups of rats,
n=5: Sham (open squares), untreated ischemic (filled triangles, saline), ischemic treated with normoxic EV (filled circles,
EXO), and ischemic treated with IPC EV (filled diamonds, IPC EXO). Time zero designates day of ischemia/reperfusion;
EV or saline were injected 1 and 2 days postischemia. (*) Next to sham symbols indicate significantly different than all
others (P<0.05). (*) Next to IPC EXO symbols indicate significant difference from saline (P<0.05), and (§) indicates
significantly different from EXO (P<0.05). (*) Next to EXO symbols designate significant difference from saline (P<0.05).
Right: Kidney weights corrected for body weight. (*) On saline (untreated ischemia) bar indicates significantly different
than all others. (*) On EXO and IPC EXO indicate significantly different than sham (P<0.05).
Figure 3.
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Improved renal structure after treatment with EV. (A) Representative images of renal sections stained with PAS. Left to
right: sham rats, ischemic untreated rats (saline), ischemic rats treated with normoxic EV (EXO), and ischemic rats treated
with IPC EV (IPC EXO). Tubular damage was widespread in untreated ischemia, including cystic-like tubular dilation.
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These changes were partly corrected by EXO, and even more by IPC EXO. In the bar diagram is shown the mean fraction
of damaged tubules per field in each group: sham (n=20) and saline groups (n=20) were significantly different
(P=2.03×10 ); sham and EXO (n=20; P=1.27 ) and sham and IPC EXO (n=20; 8.92 ) were also significantly
different; EXO was significantly higher than IPC EXO (P=1.37 ). (*) Represents significantly different from sham, and
(§) indicates significant difference between IPC EXO and EXO, P<0.05 for both. Specific renal proapoptotic transcripts
were significantly activated by untreated ischemia (NS) when compared with sham or IPC EV–treated ischemic rats (IPC)
(P<0.05). (B) Representative images of renal HNE. Heavy formation of HNE adducts was seen in untreated ischemic
(saline) rats, whereas it was nearly undetectable in sham rats. Treatment with normoxic EV (exosome) or IPC EV (IPC
EXO) limited the formation of HNE adducts. The bar diagram shows that HNE formation in the saline group (n=13) was
significantly higher than in sham (n=5; P=2.74×10 ); sham and EXO (n=5) groups were also significantly different
(P=0.02), but sham and IPC EXO (n=6) groups were not (P=0.05). EXO (P<0.01) and EXO IPC groups (P<0.001) were
lower than the untreated ischemic group, whereas the IPC EXO group was lower than the EXO group (P<0.05). (*)
Significantly different than sham group, P<0.05. Specific redox-related gene transcripts were reduced in the untreated
ischemia group with respect to sham and also IPC EXO groups, indicating partial restoration of redox gene expression by
IPC EXO treatment. In contrast, the pro-oxidant gene Olr (or Lox1) was activated in ischemia with respect to sham, and it
was reduced by IPC EXO treatment. (C) Representative images of renal sections labeled with anti-neutrophil antibody.
Large congregations of neutrophils were detected in the interstitial and intraluminal spaces of kidneys from untreated
ischemic rats (saline), whereas were barely seen in kidneys of sham rats. In contrast, ischemic rats treated with EXO or IPC
EXO had much lower numbers of neutrophils. The bar diagram shows mean neutrophil number per 400× field (PMN/hpf)
in sham rats (sham, n=27 fields), untreated ischemic (saline, n=47), ischemic rats treated with normoxic EV (EXO, n=31),
and ischemic rats treated with IPC EV (IPC EXO, n=32). Sham and saline groups were significantly different
(P=1.94×10 ), sham and EXO groups were also significantly different (P=1.05×10 ), but sham and IPC EXO groups
were not (P=0.65). In addition, EXO (P=8.74×10 ) and IPC EXO (P=2.72×10 ) were significantly lower than saline, and
IPC EXO was significantly lower than EXO (P<0.001). Proinflammatory renal transcripts, activated in untreated ischemia
and compared with sham rats or IPC-treated ischemic rats by fold change, include cytokines, chemokines, complement
components, and adhesion molecules. In most cases, IPC EXO partly corrected the activation induced by ischemia (NS).
(D) Glomerular complement C3 expression in sham rats was nearly undetectable, but it was heavily expressed in untreated
ischemic rat kidneys. Treatment with EXO and IPC EXO limited C3 expression in ischemic rats. The bar diagram shows
average pixel density of C3 immunofluorescence per 400× power field in sham rats (sham, n=24 fields), untreated ischemic
(saline, n=16), ischemic rats treated with normoxic EV (EXO, n=8), and ischemic rats treated with IPC EV (IPC EXO,
n=24). Saline was higher than sham group (P=5.97×10 ); sham and EXO were also significantly different
(P=1.13×10 ), as well as sham and IPC EXO (P=1.78×10 ). In addition, EXO (P<0.001) and IPC EXO (9.43×10 )
were significantly lower than saline, and IPC EXO was significantly lower than EXO (P<0.01). (*) Significantly different
than sham group, P<0.05; (§) indicates significant difference between IPC EXO and EXO, P<0.05. (E) Representative
images of renal sections stained with Masson’s trichrome. In untreated ischemia (saline), interstitial renal fibrosis (blue)
was extensive and replaced normal epithelia (red) when compared with controls (sham). Treatment of ischemia with
normoxic EV (exosome) or IPC EV (IPC EXO) limited fibrosis. The bar diagram shows average fractional fibrosis in
control (sham, n=16), untreated ischemia (saline, n=20), ischemia treated with normoxic EV (EXO, n=20), and ischemia
treated with IPC EV (IPC EXO, n=20). Sham and saline were significantly different (P=2.94×10 ), sham and EXO were
also significantly different (P<0.01), but sham and IPC EXO were not (P=0.08). In addition, EXO (P<0.001) and IPC EXO
(P=3.31×10 ) were significantly lower than saline, and IPC EXO was significantly lower than EXO (P<0.02). (*)
Significantly different than sham, P<0.05; (§) indicates significant difference between IPC EXO and EXO, P<0.05.
Untreated ischemia (NS) activated a suite of profibrotic transcripts and the fold change among NS and sham and IPC EV
(IPC EXO) is shown. These activated transcripts encoded extracellular matrix proteins, three members of the TGFb family,
metalloproteinases, inhibitors of metalloproteinases, transcription factors, and other genes linked to renal fibrosis. (F)
Representative images of renal peritubular microvasculature labeled with DyLight 594 conjugated Lycopersicon
Esculentum (tomato lectin, LEL, red). The microvasculature was far less dense in untreated ischemia (saline, n=92) than in
sham (n=62). However, treatment with normoxic EV (EXO, n=53) or IPC EV (IPC EXO, n=81) preserved microvascular
networks in ischemic kidneys. The bar diagram shows the average fractional (fluorescence) positivity; sham and saline
were significantly different (P=2.03 ), EXO (P=1.27 ) and IPC EXO (P=8.92 ) were also significantly lower than
sham. However, EXO (P=8.81 ) and IPC EXO (P=7.80 ) were also significantly higher than saline, whereas IPC EXO
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was significantly higher than EXO (P=1.37 ). (*) Significantly different than sham, P<0.05; (§) indicates significant
difference between IPC EXO and EXO, P<0.05. Untreated ischemia (NS) inhibited key proangiogenic transcripts, but also
activated others—Ang, Adra, Cyr61, as well as antiangiogenic Thbs1. The significant (P<0.05) fold change among NS and
sham and IPC EV (IPC EXO) is shown. Hpf, high power field; PAS, periodic acid Schiff; PMN, polymorphonuclear; V,
versus.
Figure 4.
Correction of transcriptome alterations after treatment with EV. Top, significantly altered genes with respect to control
(sham) in untreated ischemia (saline = 3141 altered genes), treatment with normoxic EV (EXO = 1599 altered genes), and
treatment with IPC EV (IPC EXO = 71 altered genes). A total of 12,159 transcripts were sequenced and identified per
group. Bottom, multidimensional scaling plot, where distances correspond to leading log–fold changes between each pair of
samples. The leading log–fold change is the average (root mean square) of the largest absolute log–fold changes between
each pair of samples. The larger shapes represent the mean for the transcriptomes in each group and the smaller shapes
represent individual rat transcriptomes. Filled diamonds = sham; gray triangles = untreated ischemic; striped circles =
ischemic treated with normoxic, or neutral, EV; and speckled squares = treated with IPC EV. FC, fold change; Vs, versus.
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